Clinical Trial Details

Overview

Research Study Summary

A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease

Purpose
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
To Learn more

CW ID: 222922
Date Last Changed: February 3, 2017

Clinical Trial Snapshot

Phase
2
Gender
Both Male and Female
Age
45 to 80 Years
Overall Status
Recruiting
Lead Sponsor
Pfizer
Facility Type
N/A

Eligibility

Inclusion Criteria:
  • Females of non-childbearing potential and/or male subjects
  • Clinical diagnosis of Parkinson's disease.
  • Parkinson's Disease Hoehn & Yahr Stage I-III inclusive
  • Treatment naïve or history of prior incidental treatment with dopaminergic agents for no more than 28 days
  • Able to refrain from any Parkinson's disease medication not permitted by the protocol.

    Exclusion Criteria:

  • History or presence of atypical Parkinsonian syndrome.
  • Severe acute or chronic medical or psychiatric condition or cognitive impairment or laboratory abnormality.
  • Any condition possibly affecting drug absorption.
  • Participation in other studies involving investigational drug(s), or treatment with any investigational drug within 30 days.
  • Contact

    Leigh Donharl
    University of South Florida - USF Health Byrd Alzheimer's Institute
    4001 Fletcher Ave
    Tampa, FL 33613
    Phone: (813) 396-0763

    View Map

    DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.